Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn
Completed · Phase 3 · Has a placebo group
Conditions studied: Burns
In brief
The purpose of the study is to see if a medication (Recombinant Coagulation Factor VIIa or NovoSeven), normally used to stop bleeding in persons with a bleeding disorder, will lower the amount of blood lost during burn surgery.
Key facts
- Study ID
- NCT00243243
- Run by
- United States Army Institute of Surgical Research
- People needed
- 20
- Starts
- 2006-01-01
- Expected to finish
- 2011-07-01
- Last updated by the study team
- 2016-05-26
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female
- Burn wounds
- 18-65 years of age
- Scheduled excision of burn wound of at least 20 percent TBSA
You may not qualify if…
- Age greater than 65 years
- History of blood coagulation disorders
- Taking anti-coagulation medication
- Contraindication for heparin therapy
- Pregnant or nursing females
- Unstable angina
- MI within the last 6 months
- Recent of diagnosis of DVT, stroke within the last 6 months
- Renal failure requiring dialysis or creatinine clearance less than 25 ml/min
- Religious prohibition to blood transfusion
- Have received rFVIIa during current hospitalization
- Previous enrollment in this study
Where it is running
- United States Army Institute of Surgical Research — Fort Sam Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.